Note; this is just for awareness ask your doctor regarding this. and be caution with your doctor too. becuase they are busy and follow the protocol get some knowledge from their experience.
| Feature / Parameter | Topiroxostat | Febuxostat |
|---|---|---|
| Drug Class | Xanthine oxidase inhibitor (non-purine) | Xanthine oxidase inhibitor (non-purine) |
| Mechanism of Action | Inhibits both oxidized & reduced forms of xanthine oxidase | Primarily inhibits oxidized xanthine oxidase |
| Used For | Hyperuricemia with or without gout | Hyperuricemia with gout |
| Brand Names | Topiloric (Japan), various generics | Uloric, Feburic, Febustat |
| Approval (Region) | Approved mainly in Japan | Approved globally (US, EU, Asia) |
| Dosing | 20–120 mg/day | 40–120 mg/day |
| Liver Metabolism | Mainly hepatic (CYP-independent) | Hepatic (CYP1A2, CYP2C8, CYP2C9) |
| Excretion | Bile and urine | Bile and urine |
| Effect on Uric Acid | Rapid and sustained reduction | Rapid and sustained reduction |
| Safety in CKD Patients | Considered safer in mild to moderate CKD | Used with caution in CKD |
| Common Side Effects | Liver enzyme elevation, rash | Liver enzyme elevation, cardiovascular risk |
| Cardiovascular Risk | Lower reported CV risk (limited data) | Increased CV risk (boxed warning in US) |
| Cost/Availability | Less globally available, cost-effective in Japan | Widely available, higher cost in some markets |
a table showing uric acid levels (mg/dL) and the typical dosages of Topiroxostat and Febuxostat used at each level or treatment stage. Please note that exact dosages should always be determined by a physician based on patient-specific factors such as renal function and comorbidities.
Uric Acid Levels vs. Topiroxostat and Febuxostat Dosage
| Uric Acid Level (mg/dL) | Topiroxostat Dosage | Febuxostat Dosage |
|---|---|---|
| >7.0 – ≤8.0 | 40 mg/day | 40 mg/day |
| >8.0 – ≤9.0 | 60 mg/day | 40–80 mg/day |
| >9.0 – ≤10.0 | 80 mg/day | 80 mg/day |
| >10.0 – ≤12.0 | 100–120 mg/day (adjust as needed) | 80–120 mg/day |
| >12.0 | Up to 120 mg/day (max dose) | Up to 120 mg/day (max dose) |
| Target Uric Acid | <6.0 mg/dL (goal in gout therapy) | <6.0 mg/dL (goal in gout therapy) |
Notes:
-
Topiroxostat is often started at a lower dose and gradually titrated based on response and tolerability.
-
Febuxostat has a recommended starting dose of 40 mg/day, which may be increased to 80 or 120 mg/day if the serum uric acid target (<6 mg/dL) is not achieved.
-
Dose adjustment may be required in renal or hepatic impairment.
-
Both drugs are not used during acute gout flares, but rather for long-term urate-lowering therapy.
is topiroxostat vs febuxostat same dose equal
High-Dose Problems: Topiroxostat vs Febuxostat
| Aspect | Topiroxostat (High Dose: 120 mg/day) | Febuxostat (High Dose: 120 mg/day) |
|---|---|---|
| Liver Toxicity | Elevated liver enzymes (dose-dependent) | Elevated liver enzymes (monitor LFTs regularly) |
| Kidney Impact | Generally safer in mild/moderate CKD; monitor Cr levels | Caution in renal impairment; dose adjustment may be needed |
| Cardiovascular Risk | Low data on CV events; relatively safer | ↑ Risk of heart attack, stroke (Black box warning in US) |
| Skin Reactions | Rash, pruritus (mild to moderate) | Rash, hypersensitivity (including Stevens-Johnson Syndrome) |
| GI Symptoms | Nausea, diarrhea, abdominal pain | Nausea, diarrhea, abdominal pain |
| Drug Interactions | Fewer (non-CYP metabolism) | Metabolized via CYP enzymes; more potential interactions |
| Hyperuricemia Rebound | Rebound possible if stopped suddenly | Rebound uric acid spike and gout flares possible |
| Other Concerns | Mild hematologic effects (rare) | Potential serious allergic reactions (rare) |
Key Warnings:
-
Febuxostat at high doses is associated with an increased risk of cardiovascular death, especially in patients with pre-existing heart disease.
-
Topiroxostat, while not linked strongly to cardiovascular risks, still requires regular monitoring of liver function tests at higher doses.
-
Sudden discontinuation of either drug can cause gout flares due to rebound hyperuricemia.
Summary:
-
Use Topiroxostat cautiously at high doses, especially monitoring liver function.
-
Use Febuxostat with extra caution in patients with cardiac history due to elevated CV risk.
Uric acide blood level mesurments
- Adult males: 3.4 to 7.0 mg/dL.
- Adult females: 2.4 to 6.0 mg/dL.
- Children: 2.0 to 5.5 mg/dL.
-
High levels (hyperuricemia):Greater than 7.0 mg/dL in men and 6.0 mg/dL in women can indicate gout, kidney problems, or other health issues.
-
Low levels:
Less than 3.0 mg/dL can be associated with certain genetic or metabolic disorders, or the use of certain medications.
- Diet: Consuming foods high in purines (like red meat, seafood, and certain alcoholic beverages) can increase uric acid levels.
- Medical conditions: Conditions like kidney disease, diabetes, and hypothyroidism can affect uric acid levels.
- Medications: Certain medications, like diuretics, can also influence uric acid levels.
my personal story:
my Uric acid level at the time of test in sumer may 11mg/dl other lab next day 10mg/dl
doctor prescribed topiroxostat 20mg twice daily along with painkillers like goutnil. i am not intrestred in swallowing pills my age 34.
i eat large amount of meat approx daily 200-300 grams.. and alchohol beer , sugar beverages… Beer trigeering ankle pain which is injured on running on cement concrete road. at weekly burst 500grams meat and 2 beers.
I tried 3-4 days once 20mg for 5 days.. and disconinued after few weeks My uric acid 8.5mg/dl other lab. reduced meat & avoided alchohol
to occasaional, after 1 year before summber its 6.5mg/dl. felt happy.
started eating meat for 2 weeks and final 1 beer before that 350ml beer next day triggered ankle pain and eventually pain gone. but after few days again started eating & drinking alchol its triggering … feeling like permanent disabled man with ankle pain..
Kidney Impact: Topiroxostat vs Febuxostat
| Aspect | Topiroxostat | Febuxostat |
|---|---|---|
| Renal Excretion | Partially renal, mostly hepatic | Minimal renal; mostly hepatic (via CYP enzymes) |
| Use in CKD Patients | Generally safer in mild to moderate CKD (Stages 1–3) | Can be used in CKD, but requires caution and monitoring |
| Dose Adjustment in CKD | Usually not required up to moderate CKD | May require dose consideration in moderate-to-severe CKD |
| Renoprotective Potential | Some studies show reduced albuminuria and renal markers | No proven renoprotective effects; mostly neutral |
| Nephrotoxicity | Rare; mild increases in creatinine in some patients | Rare; generally not nephrotoxic, but monitor in CKD |
| Acute Kidney Injury Risk | Low, especially when hydration is adequate | Low, but increased risk if overused or with other nephrotoxic drugs |
| Clinical Recommendation | Preferred in gout patients with CKD in Japan | Used in CKD globally but monitor renal parameters |
Key Takeaways:
-
Topiroxostat may have mild renoprotective benefits, especially in diabetic or hypertensive patients, by reducing urinary albumin excretion.
-
Febuxostat, while safe in general renal populations, is associated with a higher need for renal function monitoring, especially in severe CKD (Stage 4–5).
-
Both drugs are preferred over allopurinol in some CKD cases due to better safety at higher uric acid levels.
Liver Effects: Topiroxostat vs Febuxostat
| Aspect | Topiroxostat | Febuxostat |
|---|---|---|
| Metabolism | Primarily hepatic (non-CYP pathways) | Hepatic (via CYP1A2, CYP2C8, CYP2C9 enzymes) |
| Liver Enzyme Elevation | Mild to moderate ↑ in ALT/AST possible | Mild to moderate ↑ in ALT/AST common |
| Liver Injury Risk | Rare; isolated reports of hepatic dysfunction | Rare but includes serious liver injury cases |
| Dose-Related Hepatotoxicity | Higher doses may increase liver enzyme levels | More pronounced at 80–120 mg doses |
| Monitoring Recommendations | LFTs (liver function tests) before and during use | Baseline and periodic LFTs advised |
| Reversibility | Usually reversible after dose reduction/stopping | Often reversible; discontinue if persistent |
Warnings & Recommendations:
-
Routine LFT monitoring is essential for both drugs—especially in:
-
Patients on long-term therapy
-
Patients with pre-existing liver disease
-
Those taking other hepatotoxic drugs
-
-
Symptoms of liver dysfunction (that warrant immediate attention):
-
Jaundice (yellowing of skin/eyes)
-
Fatigue
-
Abdominal pain (especially right upper quadrant)
-
Dark urine, pale stools
-
Summary:
-
Topiroxostat has a lower risk of liver injury, but liver enzymes can still rise, especially with high doses.
-
Febuxostat has a higher potential for liver toxicity, especially when used in high doses or combined with other hepatotoxic medications.
-
Both require regular liver function tests (LFTs) during treatment.
Cardiovascular Effects: Topiroxostat vs. Febuxostat
| Aspect | Topiroxostat | Febuxostat |
|---|---|---|
| Cardiovascular Safety Profile | Considered relatively safer for the heart (limited long-term data) | Increased risk of cardiovascular events in some patients |
| Clinical Trial Findings | No major CV signal in studies (mostly Japanese populations) | CARES trial (2018) showed ↑ risk of CV death and all-cause death |
| US FDA Warning |  No specific cardiovascular warning issued |
Black box warning added due to CV risk |
| Use in Heart Disease Patients | May be used with monitoring | Should be avoided in patients with known CV disease unless no alternative |
| Blood Pressure or Pulse | No significant change reported | Some reports of hypertension, palpitations, chest pain |
| Mechanism of Concern | Unknown; likely low direct CV impact | May affect vascular function, oxidative stress, or heart rhythm |
Clinical Summary:
-
Febuxostat is associated with increased cardiovascular mortality, particularly in patients with existing heart disease, as seen in the CARES trial (published in NEJM, 2018).
-
Topiroxostat has limited global data, but no strong link to cardiovascular issues has emerged so far. It is primarily used in Japan, where studies have not shown increased CV risk.
Recommendation:
-
Patients with heart disease: Prefer Topiroxostat (if available) or Allopurinol.
-
Healthy individuals: Febuxostat can be used, but regular monitoring of heart health is advised.
-
Always consult a cardiologist or physician if there’s any history of MI, angina, stroke, or arrhythmia before starting these drugs.
Gastrointestinal Effects: Topiroxostat vs. Febuxostat
| GI Effect | Topiroxostat | Febuxostat |
|---|---|---|
| Nausea | Occasionally reported; mild to moderate | Common; more frequently reported in trials |
| Diarrhea | Rare to occasional | Fairly common; dose-dependent |
| Abdominal Pain | Mild abdominal discomfort in some patients | Reported in a small percentage of users |
| Vomiting | Rare | Occasional; may occur with higher doses |
| Dyspepsia (Indigestion) | Mild cases possible | Reported; may affect medication compliance |
| Gastritis / Gastric Irritation | Rare and not commonly observed | Rare, but can occur, especially with comorbid GI conditions |
| Appetite Loss | Very rare | Uncommon, usually transient |
Observations:
-
Febuxostat tends to have a higher frequency of GI side effects, particularly nausea and diarrhea, especially at 80–120 mg/day.
-
Topiroxostat shows fewer GI adverse effects, likely due to a different metabolic and chemical profile.
-
GI symptoms with both drugs are usually mild and self-limiting, but monitoring is essential in patients with existing GI disorders (e.g., GERD, peptic ulcers).
Tips to Reduce GI Side Effects:
-
Take the medication after meals to reduce stomach upset.
-
Avoid alcohol and NSAIDs, which can worsen gastric irritation.
-
Maintain adequate hydration and fiber intake.
-
Notify your doctor if GI symptoms are persistent or worsening.
Uric Acid Reduction After 30 Days with ULT drugs
if a patient has a uric acid level of 10 mg/dL and starts Topiroxostat 40 mg/day or Febuxostat 40 mg/day for 30 days, here’s what typically happens in clinical practice:
reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC9817311/
Expected Uric Acid Reduction After 30 Days
| Drug | Starting Dose | Expected Uric Acid Reduction in 30 Days | Estimated Final Level |
|---|---|---|---|
| Topiroxostat | 40 mg/day | ~20–30% reduction | ~7.0–8.0 mg/dL |
| Febuxostat | 40 mg/day | ~30–40% reduction | ~6.0–7.0 mg/dL |
Explanation:
-
Febuxostat at 40 mg/day has a stronger urate-lowering effect in most patients compared to Topiroxostat at the same dose.
-
Both drugs work gradually. Maximum effect is usually seen within 2–4 weeks, but full stabilization might take up to 3 months.
-
Response can vary based on:
-
Kidney function
-
Diet
-
Baseline uric acid production
-
Adherence and co-medications
-
Clinical Notes:
-
The target uric acid in gout/hyperuricemia is <6 mg/dL.
-
If after 30 days, levels remain >6.5–7 mg/dL, the dose is usually increased to 80 mg/day.
-
Always recheck uric acid and liver/kidney function after 4–6 weeks.
Here’s a simple Uric Acid Monitoring & Dose Titration Chart for patients starting Topiroxostat or Febuxostat with a uric acid level of 10 mg/dL:
Uric Acid Monitoring & Dose Titration Schedule (30–90 Days)
| Time | Dose (Topiroxostat) | Dose (Febuxostat) | Expected Uric Acid Level | Action |
|---|---|---|---|---|
| Day 0 | 40 mg/day | 40 mg/day | 10.0 mg/dL | Start therapy |
| Day 30 | 40–60 mg/day | 40–80 mg/day | 6.5–8.0 mg/dL | If >6.0 mg/dL, increase dose |
| Day 60 | 60–80 mg/day | 80–120 mg/day | 5.5–6.5 mg/dL | Continue current dose if <6.0 mg/dL |
| Day 90 | 80–120 mg/day (if needed) | 80–120 mg/day (if needed) | <6.0 mg/dL (target) | Maintain dose, regular monitoring |
Monitoring Checklist
-
Check uric acid every 30 days until <6 mg/dL -
Monitor Liver Function Tests (LFTs) every 1–2 months
-
Monitor renal function (Creatinine, eGFR) at baseline and every 3–6 months -
Avoid alcohol, purine-rich foods, and dehydration -
Colchicine or NSAIDs may be prescribed for gout flare prophylaxis in early therapy
Maintenance Dose of Topiroxostat and Febuxostat
Here is a clear comparison of the maintenance doses for both medications:
| Medication | Initial Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Topiroxostat | 40 mg/day | 40–120 mg/day | 120 mg/day |
| Febuxostat | 40 mg/day | 40–80 mg/day | 120 mg/day |
Key Points:
-
Topiroxostat:
-
Initially, 40 mg/day is recommended, with possible dose adjustments based on uric acid levels and tolerability.
-
The maintenance dose typically ranges from 40 to 120 mg/day, with higher doses used for severe hyperuricemia or when uric acid levels do not adequately decrease.
-
-
Febuxostat:
-
Start at 40 mg/day for most patients.
-
If the target uric acid level (<6.0 mg/dL) is not reached, the dose can be increased to 80 mg/day.
-
The maximum dose is 120 mg/day, generally prescribed for patients with high baseline uric acid levels or poor response to the initial dose.
-
Monitoring During Maintenance:
-
Uric acid levels should be monitored every 1–3 months to assess the effectiveness of the therapy.
-
Liver function tests (LFTs) and renal function should be monitored periodically, especially in those with pre-existing liver or kidney conditions.
Gout symptoms with uric acid level
| Uric Acid Level (mg/dL) | Potential Problems / Risks | Symptoms / Effects | Long-Term Risks |
|---|---|---|---|
| >6.0 – ≤7.0 mg/dL | Mild Hyperuricemia | May be asymptomatic; slight risk of developing gout | Minimal risk of long-term complications; monitor for future progression |
| >7.0 – ≤8.0 mg/dL | Moderate Hyperuricemia | Mild joint pain, especially during or after physical activity | Increased risk of developing gout attacks; joint damage over time |
| >8.0 – ≤10.0 mg/dL | Severe Hyperuricemia | Frequent gout flares, joint swelling, pain (commonly in big toe) | Chronic gout, tophi (urate crystal deposits in tissues), kidney stones |
| >10.0 – ≤12.0 mg/dL | Very High Hyperuricemia | Intense, frequent gout attacks; persistent joint pain and swelling | Joint deformities, chronic kidney disease, kidney stones, tophi buildup |
| >12.0 mg/dL | Critical Hyperuricemia | Severe and constant pain in joints; tophi visibly forming in skin | Extensive joint destruction, permanent kidney damage, life-threatening complications (e.g., renal failure, cardiovascular risk) |
Frequency of Testing for Hyperuricemia:
| Condition / Scenario | Testing Frequency |
|---|---|
| Initial diagnosis of hyperuricemia | Once, to confirm high uric acid levels (>6 mg/dL) |
| On Uric Acid-Lowering Therapy (e.g., Topiroxostat, Febuxostat) | Every 1–3 months until target uric acid level (<6.0 mg/dL) is achieved |
| After achieving target uric acid levels (<6 mg/dL) | Every 6 months to ensure long-term management |
| During acute gout flare | Uric acid testing may not be needed during flare (diagnosed clinically) but could be tested for confirmation after flare resolves |
| In patients with renal impairment or kidney stones | Every 3–6 months for ongoing monitoring of kidney function and uric acid levels |
| For patients with history of tophi or joint damage | Every 3–6 months to monitor uric acid and prevent recurrence of tophi or further joint damage |
Key Considerations:
-
For patients on medications (e.g., Topiroxostat, Febuxostat), uric acid levels should be tested more frequently during the initial stages of treatment to ensure the drug is effectively lowering uric acid levels.
-
After achieving target levels, monitoring can be spaced out to every 6 months to ensure the patient maintains a low uric acid level.
-
Regular testing is important for patients with renal impairment or those at risk of developing kidney stones due to high uric acid.
References;
https://www.orthopaper.com/archives/2024/vol10issue2/PartA/10-2-2-720.pdf
Ask a Question: